Biocurex to Collaborate With Moscow Research Center

(Richmond, Canada) has announced a collaboration with the Blokhin Cancer Research Center in Moscow (Russia) for further development and evaluation of its Recaf technology. This technology identifies a cancer marker that is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

This new phase of the BioCurex/Blokhin collaboration is centered on the use of the Recaf marker for cancer screening, diagnosis, and follow-up of treated patients using serum samples. The Blokhin Cancer Research Center is one of the largest in Europe, employing 700 scientists and 2,000 medical personnel. The enterprise comprises four separate institutes, including a 1,600 bed hospital devoted to cancer patients.
Dr. Moro, CEO of BioCurex, noted, "This collaboration is very welcome because we shall have direct access to patients, to their final diagnosis, biopsies, and serum in a comprehensive way. The access to hundreds of well-documented samples, as well as the opportunity to do prospective studies is extremely important. It will allow us to characterize and adjust the assays to the practical needs in the laboratory routine, as well as gather data to present to regulatory agencies. We can assert the usefulness of Recaf in the natural environment of the clinical laboratory within a cancer center.”

Professor Kushlinsky, head of the Clinical BioChemistry Laboratory of the Blokhin Cancer Research Center, stated, "As an oncology center whose vision is to see the implementation of diagnostic tests for the early detection of cancer, we are pleased to be working with BioCurex. The Recaf technology has the potential to become a diagnostic tool, which may improve the course of cancer detection and advance health care. BioCurex's studies to date have produced some promising results. We are ready to continue our collaboration with the aim of further evaluation of the utility of Recaf and we look forward to combining our resources and scientific knowledge to bring this diagnostic technology to its realization.”

The Blokhin Cancer Research Center is part of the American-Russian Cancer Alliance, which also includes the University of Maryland Greenebaum Cancer Center in Baltimore (Maryland) and the Kurchatov Institute and the Fox Chase Cancer Center in Philadelphia (Pennsylvania). The U.S. National Cancer Institute (NCI) provides the infrastructure for the alliance.



Related Links:
BioCurex